Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P12036
UPID:
NFH_HUMAN
Alternative names:
200 kDa neurofilament protein; Neurofilament triplet H protein
Alternative UPACC:
P12036; B4DYY4; Q96HF8; Q9UJS7; Q9UQ14
Background:
Neurofilament heavy polypeptide (NEFH), also known as the 200 kDa neurofilament protein, plays a crucial role in the maintenance of neuronal caliber alongside NEFL and NEFM. It is part of the neurofilament triplet proteins and is essential in mature axons, working in concert with PRPH and INA to form neuronal networks.
Therapeutic significance:
NEFH's involvement in Amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease, axonal, 2CC, highlights its potential as a target for therapeutic intervention. Understanding the role of NEFH could open doors to potential therapeutic strategies.